The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats

Journal of Pharmacological Sciences

Volumn 101, Issue 4, 2006, Pages 311-317

  Nakano, Ryosuke ^a   Kurosaki, Eiji ^a   Shimaya, Akiyoshi ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Euglycemic hyperinsulinaemic clamp; Insulin resistance; Peroxisome proliferator activated receptor ; YM440; Zucker fatty rat

Indexed keywords

1,4 BIS[4 [(3,5 DIOXO 1,2,4 OXADIAZOLIDIN 2 YL)METHYL] PHENOXY]BUT 2 ENE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; YM 440;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; MALE; NONHUMAN; OBESITY; RAT;

EID: 33747852658     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0060360     Document Type: Article

References (26)

1. Terrettaz J, Jeanrenaud B. In vivo hepatic and peripheral insulin resistance in genetically obese (fa/fa) rats. Endocrinology. 1983;112:1346-1351.
2. Terrettaz J, Assimacopoulos-Jeannet F, Jeanrenaud B. Severe hepatic and peripheral insulin resistance as evidenced by euglycemic clamps in genetically obese fa/fa rats. Endocrinology. 1986;118:674-678.
3. Bowen L, Stein PP, Stevenson R, Shulman GI. The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism. 1991;40:1025-1030.
4. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KS. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol. 1996;271:E742-E747.
5. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 1997;46:1393-1399.
6. Upton R, Widdowson PS, Ishii S, Tanaka H, Williams G. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br J Pharmacol. 1998;125:1708-1714.
7. Apweiler R, Kuhnle HF, Ritter G, Schell R, Freund P. Effect of the new oral antidiabetic agent (-)-BM 13.0913.Na on insulin resistance in lean and obese Zucker rats. Metabolism. 1995;44:577-583.
8. Murakami N, Ohta M, Hashimoto K, Kato K, Mizota M, Miwa I, et al. Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent. Eur J Pharmacol. 1996;304:129-134.
9. Mayorek N, Kalderon B, Itach E, Bar-Tana J. Sensitization to insulin induced by beta,beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in obese Zucker rats in vivo. Diabetes. 1997;46:1958-1964.
10. Maegawa H, Obata T, Shibata T, Fujita T, Ugi S, Morino K, et al. A new antidiabetic agent (JTT-501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle. Diabetologia. 1999;42:151-159.
11. Minoura H, Takeshita S, Yamamoto T, Mabuchi M, Hirosumi J, Takakura S, et al. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Eur J Pharmacol. 2005;519:182-190.
12. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
13. Sugimoto M, Takeda N, Nakashima K, Okumura S, Takami K, Yoshino K, et al. Effects of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats. Metabolism. 1998;47:783-787.
14. Khoursheed M, Miles PD, Gao KM, Lee MK, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism. 1995;44:1489-1494.
15. Sugiyama Y, Shimura Y, Ikeda H. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneimittelforschung. 1990;40:436-440.
16. Yakubu-Madus FE, Stephens TW, Johnson WT. Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione. Diabetes Obes Metab. 2000;2:155-163.
17. Kurosaki E, Nakano R, Shimaya A, Yoshida S, Ida M, Suzuki T, et al. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation. Biochem Pharmacol. 2003;65:795-805.
18. Shimaya A, Kurosaki E, Nakano R, Hirayama R, Shibasaki M, Shikama H. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism. 2000;49:411-417.
19. Kurosaki E, Momose K, Nakano R, Shimaya A, Suzuki T, Shibasaki M, et al. Hypoglycemic agent YM440 ameliorates the impaired hepatic glycogenesis after glucose loading by increasing glycogen synthase activity in obese Zucker rats. Jpn J Pharmacol. 2002;89:274-281.
20. Kurosaki E, Nakano R, Momose K, Shimaya A, Suzuki T, Shibasaki M, et al. Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker rats. Eur J Pharmacol. 2003;468:151-158.
21. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci. 1959;82:420-430.
22. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
23. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci. 2004;25:331-336.
24. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology. 2001;142:1269-1277.
25. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, et al. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung. 1990;40:156-162.
26. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y, Kato S. Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J Biol Chem. 2000;275:33201-33204.